Safety Management for Previously Treated mPDAC Receiving RAS(ON) Multi-Selective Inhibition

Authored by Natalia Gandur, published on 2026-08-25 03:03:32.0

The algorithm is broadly aligned with general oncology best practices for managing treatment-emergent adverse events (baseline assessment, patient education, early detection, supportive care, treatment holds for severe events, and protocol-directed dose modification/rechallenge). However, daraxonrasib (RMC-6236) remains investigational in mPDAC, so many drug-specific safety actions are primarily supported by early-phase trial reporting and protocol guidance rather than mature guideline-based standards. The toxicity-phenotype approach (mucositis, rash, GI toxicity) is consistent with common targeted-therapy supportive care frameworks, but the exact thresholds and interventions should be anchored to the trial protocol and CTCAE grading.

  1. Confirm previously treated mPDAC receiving RAS(ON) multi-selective inhibition
    Defines the population for this safety pathway: adults with previously treated metastatic PDAC receiving RAS(ON) multi-selective inhibition. Current clinical safety evidence is primarily daraxonrasib-specific and should not be automatically extrapolated to the entire RAS(ON) inhibitor class.
    • Baseline safety assessment
      Before treatment, assess performance status, baseline marrow, hepatic and renal function, hydration and nutritional status, baseline GI, oral and dermatologic symptoms, ability to take oral therapy, relevant comorbidities, and concomitant medications according to the applicable protocol or access plan.
      • Establish treatment-specific education and supportive-care plan
        Educate patients to report rash, oral pain or mucositis, diarrhea, nausea/vomiting, reduced oral intake, dehydration, fever, or other new clinically significant symptoms early. Reinforce hydration, nutrition, oral care, skin care, adherence, and clear contact/escalation instructions.
        • Protocol-directed daraxonrasib treatment
          Daraxonrasib remains investigational. Treatment, monitoring, interruption, dose modification, and rechallenge should follow the currently applicable clinical-trial or Expanded Access protocol. Published clinical development selected 300 mg orally once daily for phase III evaluation; this should not be described as an FDA-approved label dose.
          • Monitor for treatment-emergent toxicity
            Assess and grade treatment-emergent toxicity using CTCAE, with particular attention to rash, stomatitis/mucositis, diarrhea, nausea/vomiting, fatigue, hydration and oral intake, and any atypical or organ-threatening presentation.
            • New or worsening clinically significant treatment-emergent toxicity?
              Determine whether a new or worsening toxicity requires active supportive management, treatment interruption, or urgent evaluation.
              • Continue protocol-directed treatment and routine monitoring
                Continue protocol-directed treatment when there is no clinically significant treatment-emergent toxicity, with ongoing symptom assessment and safety monitoring according to the applicable protocol/access plan.
                • Longitudinal safety monitoring during ongoing treatment
                  Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
              • Predominant toxicity phenotype?
                Classify the predominant clinically relevant toxicity phenotype to guide supportive management and escalation.
                • Hold treatment and obtain urgent clinical evaluation
                  Hold daraxonrasib pending urgent evaluation for suspected organ-threatening toxicity, severe cutaneous reaction, severe dehydration or AKI, hemodynamic instability, significant hepatic injury, or another clinically serious or atypical presentation.
                  • Reassess toxicity after intervention
                    Reassess clinical severity, symptom trajectory, hydration and oral intake, relevant organ function, and any laboratory abnormality related to the toxicity phenotype before determining whether ongoing treatment remains appropriate.
                    • Toxicity adequately controlled and treatment clinically appropriate to continue?
                      Determine whether toxicity has resolved or improved sufficiently for continued treatment, whether protocol-directed treatment modification is required, or whether continued treatment is no longer clinically appropriate.
                      • Continue protocol-directed treatment with ongoing monitoring
                        When toxicity is adequately controlled without treatment modification, continue protocol-directed treatment with ongoing monitoring for recurrence or new treatment-emergent toxicity.
                        • Longitudinal safety monitoring during ongoing treatment
                          Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
                      • Resume according to the current protocol-directed modification plan
                        If rechallenge is permitted, resume treatment only after the patient is clinically stable and toxicity has recovered to the level required by the applicable protocol/access plan. Use the protocol-specified dose or schedule and optimize supportive measures appropriate to the prior toxicity.
                        • Longitudinal safety monitoring during ongoing treatment
                          Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
                      • Discontinue treatment and transition to appropriate oncology care
                        When toxicity is recurrent, intolerable, unsafe for continued treatment, or the applicable protocol/access plan does not permit further rechallenge, discontinue daraxonrasib and transition to the appropriate oncology management pathway.
                • Manage GI toxicity and hydration
                  Manage diarrhea, nausea/vomiting, and dehydration early with supportive therapy, oral or IV hydration as clinically indicated, and correction of clinically significant electrolyte or renal abnormalities.
                  • Reassess toxicity after intervention
                    Reassess clinical severity, symptom trajectory, hydration and oral intake, relevant organ function, and any laboratory abnormality related to the toxicity phenotype before determining whether ongoing treatment remains appropriate.
                    • Toxicity adequately controlled and treatment clinically appropriate to continue?
                      Determine whether toxicity has resolved or improved sufficiently for continued treatment, whether protocol-directed treatment modification is required, or whether continued treatment is no longer clinically appropriate.
                      • Continue protocol-directed treatment with ongoing monitoring
                        When toxicity is adequately controlled without treatment modification, continue protocol-directed treatment with ongoing monitoring for recurrence or new treatment-emergent toxicity.
                        • Longitudinal safety monitoring during ongoing treatment
                          Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
                      • Resume according to the current protocol-directed modification plan
                        If rechallenge is permitted, resume treatment only after the patient is clinically stable and toxicity has recovered to the level required by the applicable protocol/access plan. Use the protocol-specified dose or schedule and optimize supportive measures appropriate to the prior toxicity.
                        • Longitudinal safety monitoring during ongoing treatment
                          Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
                      • Discontinue treatment and transition to appropriate oncology care
                        When toxicity is recurrent, intolerable, unsafe for continued treatment, or the applicable protocol/access plan does not permit further rechallenge, discontinue daraxonrasib and transition to the appropriate oncology management pathway.
                • Manage stomatitis / mucositis with oral supportive care
                  Use severity-based oral supportive care, including meticulous oral hygiene, bland rinses, symptom control, hydration, and nutritional support. Evaluate for superimposed infection when clinically suspected.
                  • Reassess toxicity after intervention
                    Reassess clinical severity, symptom trajectory, hydration and oral intake, relevant organ function, and any laboratory abnormality related to the toxicity phenotype before determining whether ongoing treatment remains appropriate.
                    • Toxicity adequately controlled and treatment clinically appropriate to continue?
                      Determine whether toxicity has resolved or improved sufficiently for continued treatment, whether protocol-directed treatment modification is required, or whether continued treatment is no longer clinically appropriate.
                      • Continue protocol-directed treatment with ongoing monitoring
                        When toxicity is adequately controlled without treatment modification, continue protocol-directed treatment with ongoing monitoring for recurrence or new treatment-emergent toxicity.
                        • Longitudinal safety monitoring during ongoing treatment
                          Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
                      • Resume according to the current protocol-directed modification plan
                        If rechallenge is permitted, resume treatment only after the patient is clinically stable and toxicity has recovered to the level required by the applicable protocol/access plan. Use the protocol-specified dose or schedule and optimize supportive measures appropriate to the prior toxicity.
                        • Longitudinal safety monitoring during ongoing treatment
                          Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
                      • Discontinue treatment and transition to appropriate oncology care
                        When toxicity is recurrent, intolerable, unsafe for continued treatment, or the applicable protocol/access plan does not permit further rechallenge, discontinue daraxonrasib and transition to the appropriate oncology management pathway.
                • Manage rash with supportive dermatologic care
                  For non-severe daraxonrasib-associated rash, use severity-based supportive dermatologic care and monitor for progression. Blistering, mucosal involvement, systemic symptoms, or other features concerning for severe cutaneous toxicity should transition to the urgent-evaluation branch.
                  • Reassess toxicity after intervention
                    Reassess clinical severity, symptom trajectory, hydration and oral intake, relevant organ function, and any laboratory abnormality related to the toxicity phenotype before determining whether ongoing treatment remains appropriate.
                    • Toxicity adequately controlled and treatment clinically appropriate to continue?
                      Determine whether toxicity has resolved or improved sufficiently for continued treatment, whether protocol-directed treatment modification is required, or whether continued treatment is no longer clinically appropriate.
                      • Continue protocol-directed treatment with ongoing monitoring
                        When toxicity is adequately controlled without treatment modification, continue protocol-directed treatment with ongoing monitoring for recurrence or new treatment-emergent toxicity.
                        • Longitudinal safety monitoring during ongoing treatment
                          Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
                      • Resume according to the current protocol-directed modification plan
                        If rechallenge is permitted, resume treatment only after the patient is clinically stable and toxicity has recovered to the level required by the applicable protocol/access plan. Use the protocol-specified dose or schedule and optimize supportive measures appropriate to the prior toxicity.
                        • Longitudinal safety monitoring during ongoing treatment
                          Continue longitudinal assessment of treatment-emergent toxicity, functional status, oral intake, hydration/nutrition, and relevant laboratory parameters throughout ongoing treatment.
                      • Discontinue treatment and transition to appropriate oncology care
                        When toxicity is recurrent, intolerable, unsafe for continued treatment, or the applicable protocol/access plan does not permit further rechallenge, discontinue daraxonrasib and transition to the appropriate oncology management pathway.
  2. Current evidence base: daraxonrasib (RMC-6236)
    Current clinical evidence for this safety pathway is derived primarily from daraxonrasib (RMC-6236), including the published phase 1/2 study and phase III RASolute 302. Daraxonrasib remains investigational in the United States; FDA has permitted an Expanded Access treatment protocol for eligible patients with previously treated metastatic PDAC.
  3. Dose modification and rechallenge — protocol-specific
    Exact dose-reduction levels, hold durations, restart criteria, and rechallenge conditions are protocol/access-plan specific and should not be extrapolated from class-based guidance or publication summaries.
tosprivacyO'Reilly EM, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026;395:325-337.Wolpin BM, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026;394:1790-1802.RASolute 302: Phase 3 Study of Daraxonrasib (RMC-6236) in Previously Treated Metastatic PDAC. ClinicalTrials.gov NCT06625320.NCCN Clinical Practice Guidelines in Oncology: Pancreatic AdenocarcinomaFDA. FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug. May 1, 2026.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute.Elad S, et al. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy. Cancer. 2020;126:4423-4431.Lacouture ME, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:157-170.Bossi P, et al. Diarrhoea in Adult Cancer Patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv126-iv142.Herrstedt J, et al. 2023 MASCC and ESMO Guideline Update for the Prevention of Chemotherapy- and Radiotherapy-Induced Nausea and Vomiting. ESMO Open. 2024;9:102195.Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS. ClinicalTrials.gov NCT05379985.Wolpin BM, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma: RASolute 302. J Clin Oncol. 2026;44(17_suppl):LBA5.